Please assess the completion status of the following clinical trial:

Trial Title: Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* A histologically confirmed diagnosis of PTCL~* Participants must have relapsed or refractory disease after at least one prior systemic anticancer regimen. Systemic anticancer therapy is defined as chemotherapy or immunotherapy administered systemically.~* Participants must have at least one site of disease measurable in two dimensions by computed tomography (CT).~* Age ≥ 18 years.~* Adequate bone marrow, liver, and renal functions.~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2.~* Negative pregnancy test for women of childbearing potential.~Exclusion criteria:~* Relapse within 100 days of autologous or allogeneic bone marrow transplant.~* Prior histone deacetylase (HDAC) inhibitor therapy.~* Co-existing active infection or any medical condition likely to interfere with trial procedures.~* Severe cardiovascular disease.~* Clinically significant central nervous system disorders with altered mental status or psychiatric disorders precluding understanding of the informed consent process and/or completion of the necessary studies.~* Active concurrent malignancy (except adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix).~* Symptomatic or untreated central nervous system (CNS) metastases.~* Pregnant or breast-feeding women.~* Known infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Belinostat (Type: EXPERIMENTAL): Belinostat 1000 mg/m\^2 administered as a 30 minute IV infusion on Days 1-5 of every 3-week cycle until disease progression or unmanageable treatment-related toxicities.

Based on this trial design, predict the completion outcome and termination type (if applicable).